WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors

About half of all melanomas harbor a mutation that results in a constitutively active BRAF kinase mutant (BRAF(V600E/K)) that can be selectively inhibited by targeted BRAF inhibitors (BRAFis). While patients treated with BRAFis initially exhibit measurable clinical improvement, the majority of patie...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Anastas, Jamie N., Kulikauskas, Rima M., Tamir, Tigist, Rizos, Helen, Long, Georgina V., von Euw, Erika M., Yang, Pei-Tzu, Chen, Hsiao-Wang, Haydu, Lauren, Toroni, Rachel A., Lucero, Olivia M., Chien, Andy J., Moon, Randall T.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2014
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4071371/
https://ncbi.nlm.nih.gov/pubmed/24865425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI70156
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados